Bicalutamide plus Anastrozole for the Treatment of Gonadotropin-Independent Precocious Puberty in Boys with Testotoxicosis: A Phase II, Open-Label Pilot Study (BATT)

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 10, 2010, Pages 999-1009

  Reiter, Edward O ^a   Mauras, Nelly ^b   McCormick, Ken ^c   Kulshreshtha, Bindu ^d   Amrhein, James ^e   De Luca, Francesco ^f   O'Brien, Sandra ^g   Armstrong, Jon ^g   Melezinkova, Helena ^g  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEMOURS CHILDREN S CLINIC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e Pediatric Endocrinology and Diabetes   (United States)

^f ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Androgens; Lh receptor; Phase II; Precocious puberty; Testotoxicosis

Indexed keywords

ANASTROZOLE; BICALUTAMIDE; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ARTICLE; BODY HEIGHT; BONE AGE; BONE MATURATION; BREAST TENDERNESS; CHILD; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEVER; FOLLOW UP; GROWTH RATE; GYNECOMASTIA; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; TESTOTOXICOSIS; TREATMENT DURATION; VOMITING;

ANILIDES; BONE DEVELOPMENT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; GONADOTROPINS; GROWTH; HUMANS; MALE; NITRILES; PILOT PROJECTS; PUBERTY, PRECOCIOUS; TOSYL COMPOUNDS; TRIAZOLES;

EID: 79951473189     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2010.161     Document Type: Article

References (29)

1. Latronico AC, Lins TS, Brito VN, Arnhold IJ, Mendonca BB. The effect of distinct activating mutations of the luteinizing hormone receptor gene on the pituitary-gonadal axis in both sexes. Clin Endocrinol (Oxf) 2000; 53: 609-613.
2. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu SM, Blomberg L, Cutler GB, Jr. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci U S A 1995; 92: 1906-1910.
3. Shenker A, Laue L, Kosugi S, Merendino JJ, Jr., Minegishi T, Cutler GB, Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365: 652-654. (Pubitemid 23350536)
4. Maras A, Laucht M, Gerdes D, Wilhelm C, Lewicka S, Haack D, Malisova L, Schmidt MH. Association of testosterone and dihydrotestosterone with externalizing behavior in adolescent boys and girls. Psychoneuroendocrinology 2003; 28: 932-940. (Pubitemid 36936800)
5. Reiter EO, Norjavaara E. Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev 2005; 3: 77-86. (Pubitemid 43213210)
6. Almeida MQ, Brito VN, Lins TS, Guerra-Junior G, de CM, Antonini SR, Arnhold IJ, Mendonca BB, Latronico AC. Long-term treatment of familial malelimited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole. Clin Endocrinol (Oxf) 2008; 69: 93-98. (Pubitemid 351847269)
7. Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985; 312: 1023-1028. (Pubitemid 15114290)
8. Soriano-Guillen L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab 2005; 90: 147-151. (Pubitemid 40116648)
9. Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab 1983; 57: 571-579. (Pubitemid 13005524)
10. Itoh K, Nakada T, Kubota Y, Suzuki H, Ishigooka M, Izumi T. Testotoxicosis proved by immunohistochemical analysis and successfully treated with cyproterone acetate. Urol Int 1996; 57: 199-202. (Pubitemid 26340626)
11. Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB, Jr. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320: 496-502. (Pubitemid 19062525)
12. Laue L, Jones J, Barnes KM, Cutler GB, Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993; 76: 151-155. (Pubitemid 23027570)
13. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB, Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84: 175-178. (Pubitemid 29036697)
14. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-254.
15. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge GR. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-396. (Pubitemid 28136673)
16. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van PH, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-1582.
17. Tyrrell CJ, Iversen P, Tammela T, Anderson J, Bjork T, Kaisary AV, Morris T. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006; 98: 563-572. (Pubitemid 44185877)
18. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von EM, Sahmoud T, Webster A, Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
19. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643.
20. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83: 1142-1152. (Pubitemid 28419067)
21. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100- month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
22. Mauras N, Welch S, Rini A, Klein KO. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004; 17: 1597-1606. (Pubitemid 40044898)
23. Mauras N, Gonzalez de PL, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebocontrolled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93: 823-831. (Pubitemid 351398559)
24. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, Diamond FB, Jr., Backeljauw PF. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 4428-4433. (Pubitemid 39244450)
25. Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008; 93: 2751-2754. (Pubitemid 352008546)
26. Mauras N, Bishop K, Merinbaum D, Emeribe U, Agbo F, Lowe E. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab 2009; 94: 2975-2978.
27. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006; 149: 416-420. (Pubitemid 44308423)
28. WHO Global Database on Child Growth and Malnutrition. 2010. Available at: http://www.who.int/ nutgrowthdb/en/.
29. Hayes FJ, Seminara SB, DeCruz S, Boepple PA, Crowley WF, Jr. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 2000; 85: 3027-3035.